[Lipid metabolism and risk of myocardial infarction -- new findings and implications for treatment].
Cullen
P
P
Leibniz-Institut für Arterioskleroseforschung an der Universität Münster.
Schulte
H
H
Assmann
G
G
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000209:etiology / Q000235:genetics / Q000517:prevention & control; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006710:Homocysteine / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications* / Q000235:genetics / Q000628:therapy; D009203:Myocardial Infarction / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control; D020641:Polymorphism, Single Nucleotide; D018570:Risk Assessment
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006710:Homocysteine; D002097:C-Reactive Protein